Kaken Pharmaceutical
CompanyJapan
Kaken Pharmaceutical develops one asset, approved (trafermin in pressure ulcer). Mostly protein or enzyme acting on FGFR1 and FGFR2; based in Japan.
- 1
- Asset
- Furthest stage
- Approved
- 2
- Trials
- 0
- Signals
Pipeline
1Recombinant basic fibroblast growth factor promotes fibroblast proliferation, angiogenesis and wound healing.
Approved, Protein or enzyme, FGFR1, FGFR2, pressure ulcer, skin ulcer
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials2
- Similar companies6